Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.

摘要: Abstract The debilitating symptoms of the anemia associated with end-stage renal disease (ESRD) may have a profound effect on patients' quality life. Until now it has been difficult to differentiate caused by from those uncleared uremic toxins and other concomitant diseases. Treatment recombinant human erythropoietin (EPOGEN, AMGEN Inc, Thousand Oaks, CA) largely eliminates ESRD; therefore offers means improving life while also clarifying possible causes various symptoms. However, because involves many factors, such as self-concept, interpersonal relations, work identity, an improvement in will varying impact different individuals.